Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Docetaxel in HER2-positive Metastatic Breast Cancer
NCT03876587Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive metastatic breast cancer, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT03876587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876587.